Catalog #SIM0066
InVivoSIM anti-human GPNMB (Glembatumumab Biosimilar)
Clone
Glembatumumab
Reactivities
Human
Isotype
Human IgG2, κ
Product Description
This non-therapeutic biosimilar antibody utilizes the same variable regions as the therapeutic antibody Glembatumumab, making it ideal for research use. Glembatumumab is a fully human IgG2 monoclonal antibody that targets glycoprotein non-metastatic melanoma protein B (GPNMB), a transmembrane glycoprotein overexpressed in various cancers, including triple-negative breast cancer (TNBC), melanoma, glioblastoma, and osteosarcoma. GPNMB is associated with tumor progression, metastasis, and poor prognosis. In therapeutic applications, Glembatumumab is conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) to form the antibody-drug conjugate (ADC) Glembatumumab vedotin. This ADC binds to GPNMB-expressing tumor cells, is internalized, and releases MMAE intracellularly, leading to cell death. However, this biosimilar is unconjugated and formulated for non-therapeutic research use only, making it an excellent tool for studying GPNMB biology, tumor immunology, and the development of GPNMB-targeted therapies.
Specifications
| Isotype | Human IgG2, κ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb human IgG2 isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Immunogen | Human GPNMB |
| Reported Applications |
Functional assays Flow cytometry ELISA Immunohistochemistry Western blot |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL gel clotting assay |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from cell culture supernatant in an animal-free facility |
| Purification | Protein A |
| Molecular Weight | 150 kDa |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |